Antihypertensive efficacy of pinacidil - Automatic ambulatory blood pressure monitoring

P. K. Zachariah, S. G. Sheps, A. Schirger, L. D. Fisher, C. Shub, J. B. Collins, R. E. Spiekerman

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Forty-three patients with mild essential hypertension were randomized into two double-blind studies: pinacidil vs. placebo or pinacidil vs. hydralazine. Pinacidil (62±18 mg/day) decreased office systolic and diastolic blood pressures from 145 to 137 mm Hg and from 98 to 89 mm Hg, respectively, after 6 weeks of therapy. Similarly, hydralazine (128±28 mg/day) reduced supine systolic blood pressure from 140 to 134 mm Hg and supine diastolic blood pressure from 93 mm Hg to 84 mm Hg. Significant tachycardia was not noted with either drug. Ambulatory blood pressure was monitored for 24 h during the placebo-washout and efficacy phases with both pinacidil and hydralazine. Mean 24-h blood pressure was 128 systolic and 81 diastolic with pinacidil and 121 systolic and 76 diastolic with hydralazine. Reduction in awake hypertensive diastolic blood pressure was significant for both pinacidil and hydralazine. Normal sleep diastolic blood pressure was not reduced by pinacidil but was reduced by hydralazine. Side-effects with both drugs included edema, headache, and palpitations. These data demonstrate that pinacidil is as effective an antihypertensive agent as hydralazine.

Original languageEnglish (US)
Pages (from-to)133-141
Number of pages9
JournalEuropean Journal of Clinical Pharmacology
Volume31
Issue number2
DOIs
StatePublished - Mar 1986
Externally publishedYes

Fingerprint

Pinacidil
Ambulatory Blood Pressure Monitoring
Antihypertensive Agents
Hydralazine
Blood Pressure
Placebos
Double-Blind Method
Tachycardia
Pharmaceutical Preparations
Headache

Keywords

  • adverse effects
  • ambulatory blood pressure monitoring
  • diastolic blood pressure decrease
  • hydralazine
  • hypertension
  • pinacidil
  • vasodilation

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)

Cite this

Zachariah, P. K., Sheps, S. G., Schirger, A., Fisher, L. D., Shub, C., Collins, J. B., & Spiekerman, R. E. (1986). Antihypertensive efficacy of pinacidil - Automatic ambulatory blood pressure monitoring. European Journal of Clinical Pharmacology, 31(2), 133-141. https://doi.org/10.1007/BF00606649

Antihypertensive efficacy of pinacidil - Automatic ambulatory blood pressure monitoring. / Zachariah, P. K.; Sheps, S. G.; Schirger, A.; Fisher, L. D.; Shub, C.; Collins, J. B.; Spiekerman, R. E.

In: European Journal of Clinical Pharmacology, Vol. 31, No. 2, 03.1986, p. 133-141.

Research output: Contribution to journalArticle

Zachariah, PK, Sheps, SG, Schirger, A, Fisher, LD, Shub, C, Collins, JB & Spiekerman, RE 1986, 'Antihypertensive efficacy of pinacidil - Automatic ambulatory blood pressure monitoring', European Journal of Clinical Pharmacology, vol. 31, no. 2, pp. 133-141. https://doi.org/10.1007/BF00606649
Zachariah, P. K. ; Sheps, S. G. ; Schirger, A. ; Fisher, L. D. ; Shub, C. ; Collins, J. B. ; Spiekerman, R. E. / Antihypertensive efficacy of pinacidil - Automatic ambulatory blood pressure monitoring. In: European Journal of Clinical Pharmacology. 1986 ; Vol. 31, No. 2. pp. 133-141.
@article{8082c81407684961ac1bae567d0fe49b,
title = "Antihypertensive efficacy of pinacidil - Automatic ambulatory blood pressure monitoring",
abstract = "Forty-three patients with mild essential hypertension were randomized into two double-blind studies: pinacidil vs. placebo or pinacidil vs. hydralazine. Pinacidil (62±18 mg/day) decreased office systolic and diastolic blood pressures from 145 to 137 mm Hg and from 98 to 89 mm Hg, respectively, after 6 weeks of therapy. Similarly, hydralazine (128±28 mg/day) reduced supine systolic blood pressure from 140 to 134 mm Hg and supine diastolic blood pressure from 93 mm Hg to 84 mm Hg. Significant tachycardia was not noted with either drug. Ambulatory blood pressure was monitored for 24 h during the placebo-washout and efficacy phases with both pinacidil and hydralazine. Mean 24-h blood pressure was 128 systolic and 81 diastolic with pinacidil and 121 systolic and 76 diastolic with hydralazine. Reduction in awake hypertensive diastolic blood pressure was significant for both pinacidil and hydralazine. Normal sleep diastolic blood pressure was not reduced by pinacidil but was reduced by hydralazine. Side-effects with both drugs included edema, headache, and palpitations. These data demonstrate that pinacidil is as effective an antihypertensive agent as hydralazine.",
keywords = "adverse effects, ambulatory blood pressure monitoring, diastolic blood pressure decrease, hydralazine, hypertension, pinacidil, vasodilation",
author = "Zachariah, {P. K.} and Sheps, {S. G.} and A. Schirger and Fisher, {L. D.} and C. Shub and Collins, {J. B.} and Spiekerman, {R. E.}",
year = "1986",
month = "3",
doi = "10.1007/BF00606649",
language = "English (US)",
volume = "31",
pages = "133--141",
journal = "European Journal of Clinical Pharmacology",
issn = "0031-6970",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Antihypertensive efficacy of pinacidil - Automatic ambulatory blood pressure monitoring

AU - Zachariah, P. K.

AU - Sheps, S. G.

AU - Schirger, A.

AU - Fisher, L. D.

AU - Shub, C.

AU - Collins, J. B.

AU - Spiekerman, R. E.

PY - 1986/3

Y1 - 1986/3

N2 - Forty-three patients with mild essential hypertension were randomized into two double-blind studies: pinacidil vs. placebo or pinacidil vs. hydralazine. Pinacidil (62±18 mg/day) decreased office systolic and diastolic blood pressures from 145 to 137 mm Hg and from 98 to 89 mm Hg, respectively, after 6 weeks of therapy. Similarly, hydralazine (128±28 mg/day) reduced supine systolic blood pressure from 140 to 134 mm Hg and supine diastolic blood pressure from 93 mm Hg to 84 mm Hg. Significant tachycardia was not noted with either drug. Ambulatory blood pressure was monitored for 24 h during the placebo-washout and efficacy phases with both pinacidil and hydralazine. Mean 24-h blood pressure was 128 systolic and 81 diastolic with pinacidil and 121 systolic and 76 diastolic with hydralazine. Reduction in awake hypertensive diastolic blood pressure was significant for both pinacidil and hydralazine. Normal sleep diastolic blood pressure was not reduced by pinacidil but was reduced by hydralazine. Side-effects with both drugs included edema, headache, and palpitations. These data demonstrate that pinacidil is as effective an antihypertensive agent as hydralazine.

AB - Forty-three patients with mild essential hypertension were randomized into two double-blind studies: pinacidil vs. placebo or pinacidil vs. hydralazine. Pinacidil (62±18 mg/day) decreased office systolic and diastolic blood pressures from 145 to 137 mm Hg and from 98 to 89 mm Hg, respectively, after 6 weeks of therapy. Similarly, hydralazine (128±28 mg/day) reduced supine systolic blood pressure from 140 to 134 mm Hg and supine diastolic blood pressure from 93 mm Hg to 84 mm Hg. Significant tachycardia was not noted with either drug. Ambulatory blood pressure was monitored for 24 h during the placebo-washout and efficacy phases with both pinacidil and hydralazine. Mean 24-h blood pressure was 128 systolic and 81 diastolic with pinacidil and 121 systolic and 76 diastolic with hydralazine. Reduction in awake hypertensive diastolic blood pressure was significant for both pinacidil and hydralazine. Normal sleep diastolic blood pressure was not reduced by pinacidil but was reduced by hydralazine. Side-effects with both drugs included edema, headache, and palpitations. These data demonstrate that pinacidil is as effective an antihypertensive agent as hydralazine.

KW - adverse effects

KW - ambulatory blood pressure monitoring

KW - diastolic blood pressure decrease

KW - hydralazine

KW - hypertension

KW - pinacidil

KW - vasodilation

UR - http://www.scopus.com/inward/record.url?scp=0022914786&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022914786&partnerID=8YFLogxK

U2 - 10.1007/BF00606649

DO - 10.1007/BF00606649

M3 - Article

VL - 31

SP - 133

EP - 141

JO - European Journal of Clinical Pharmacology

JF - European Journal of Clinical Pharmacology

SN - 0031-6970

IS - 2

ER -